Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis

Journal of Infectious Diseases

Volumn 198, Issue 3, 2008, Pages 359-366

  Robinson, Cory M ^a   Nau, Gerard J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b E1256 BSTWR ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 27; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL ACTIVITY; CELL FUNCTION; CELL SURFACE; CELL VIABILITY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS;

FLOW CYTOMETRY; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; MACROPHAGES; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUBERCULOSIS;

EID: 48749121088     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/589774     Document Type: Article

References (42)

1. World Health Organization. Detailed estimates of TB burden for 2005. Available at: http://www.who.int/tb/country/tb_burden/en/index.html. Accessed 17 September 2007.
2. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001; 69:1722-8.
3. Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev 2003; 14:467-77.
4. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-α is required in the protective immune response against M. tuberculosis in mice. Immunity 1995; 2:561-72.
5. Bean AGD, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162:3504-11.
6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
7. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001; 69:1847-55.
8. Tessier PA, Naccache PH, Clark-Lewis I, Gadue RP, Neote KS, McColl SR. Chemokine networks in vivo. J Immunol 1997; 159:3595-602.
9. + T cells. J Immunol 1995; 154:5071-9.
10. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, Orme IM. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995; 84:423-32.
11. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997; 186:39-45.
12. Hölscher C, Atkinson RA, Arendse B, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001; 167:6957-66.
13. Chen Q, Ghilardi N, Wang H, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000; 407:916-20.
14. + T cells. Immunity 2002; 16:779-90.
15. Yoshida H, Hamano S, Senaldi G, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001; 15:569-78.
16. Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996; 70:1143-53.
17. Hamano S, Himeno K, Miyazaki Y, et al. WSX-1 is required for resistance to Trypanosome cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003; 19:657-67.
18. Pearl JE, Khader SA, Solache A, et al. IL-27 signaling compromises control of bacterial growth in Mycobacteria-infected mice. J Immunol 2004; 173:7490-6.
19. Wirtz S, Tubbe I, Galle PR, et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med 2006; 203:1875-81.
20. Villarino A, Hibbert L, Liebermanet L, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003; 19:645-55.
21. Grohmann U, Belladonna ML, Vacca C, et al. Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol 2001; 167:221-7.
22. Xing Z, Zganiacz A, Santosuosso M. Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction. J Leukoc Biol 2000; 68:897-902.
23. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172:2225-31.
24. Carlson PE Jr, Carroll JA, O'Dee DM, Nau GJ. Modulation of virulence factors in Francisella tularensis determines human macrophage responses. Microb Pathog 2007; 42:204-14.
25. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Landers ES, Young RA. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A 2002; 99:1503-8.
26. Hickman SP, Chan J, Salgame P. Mycobacterium tuberculosis induces differential cytokine production from dendritic cells and macrophages with divergent effects on naïve T cell polarization. J Immunol 2002; 168:4636-42.
27. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFN-γ production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001; 22:556-60.
28. Sprecher, CA, Grant FJ, Baumgartner JW, et al. Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun 1998; 246:82-90.
29. Nau GJ, Schlesinger A, Richmond JF, Young RA. Cumulative Toll-like receptor activation in human macrophages treated with whole bacteria. J Immunol 2003; 170:5203-9.
30. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-21.
31. Han, J, Brown T, Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 1990; 171:465-75.
32. Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 1991; 132:150-7.
33. Chan J, Xing Y, Magliozzo RS, Bloom B. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992;175: 1111-22.
34. Robinson BWS, McLemore TL, Crystal RG. 1985 Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75:1488-95.
35. Fenton MJ, Vermeulen MW, Kim S, Burdick M, Strieter RM, Kornfeld H. Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect Immun 1997; 65:5149-56.
36. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178:2243-7.
37. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to M. tuberculosis infection. J Exp Med 1993; 178:2249-54.
38. Jouanguy E, Altaire F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-61.
39. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941-9.
40. Jouanguy E, Salma L-C, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nature Genet 1999; 21:370-8.
41. Casanova JL, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol 2004; 4:55-66.
42. Nolt D, Flynn JL. Interleukin-12 therapy reduces the number of immune cells and pathology in lungs of mice infected with M. tuberculosis. Infect Immun 2004; 72:2976-88.